We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Nuclear Phosphatase Regulates Proteasome Activity

By LabMedica International staff writers
Posted on 10 Oct 2011
A recent paper described the discovery of a proteasome phosphatase that regulates the removal of unnecessary or damaged proteins from cells by modulating the activity of the 26S proteasome.

The ubiquitin-proteasome system (UPS) is the mechanism by which malfunctioning and possibly toxic proteins are removed from the cell. More...
This system is based on the tagging of damaged proteins with ubiquitin, and the digestion of the subsequent ubiquinated proteins by the proteasome. In the current study investigators at the University of California, San Diego (USA) and the University of California, Irvine have shed new light on the molecular mechanism that controls proteasome activity.

They reported in the September 26, 2011, online edition of the journal Proceedings of the [US] National Academy of Sciences that a 26S proteasome phosphatase called ubiquitin-like domain-containing C-terminal domain phosphatase 1 (UBLCP1) regulated nuclear proteasome activity. UBLCP1 dephosphorylated the 26S proteasome and inhibited proteasome activity in vitro. Knockdown of UBLCP1 in cells promoted 26S proteasome assembly and selectively enhanced nuclear proteasome activity. UBLCP1 directly interacted with the proteasome via its UBL domain and it was exclusively localized in the nucleus.

“So far, UBLCP1 is the only proteasome-specific phosphatase identified to exist in mammalian cells,” said senior author Dr. Jack E. Dixon professor of pharmacology, cellular, and molecular medicine at the University of California, San Diego. “We are just beginning to understand how it alters proteasome activity, but one can anticipate that defects in the phosphatase activity are likely to result in major alterations in the ability of the cell to remove damaged protein.”

Related Links:

University of California, San Diego
University of California, Irvine






Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.